Plain-English translation of NCT06925737 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Researchers are testing a new drug called (I-DXd) to see if it helps people with advanced prostate cancer live longer and keep their cancer from growing compared to standard chemotherapy. The medication is designed to target cancer cells in a specific way. This trial will enroll about 1,440 patients to compare how well this treatment works.
Prostate cancer can become resistant to hormone therapy, and doctors need better treatment options for these patients. This trial will help determine whether this new medication offers an improvement over the chemotherapy doctors currently use.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication (given as an injection every three weeks) or standard chemotherapy plus a steroid pill (also given every three weeks). You would visit the clinic regularly for treatment and monitoring, with blood tests and scans to track how your cancer responds. The study will follow you to see how long you live and whether your cancer stops growing or spreading.
AI-generated summary from trial data · Oct 6, 2026 · Not medical advice
United States